Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_151_библиотеки_им_акад_М_И_Перельмана
.pdf
286 B. N. H. M. Neeroa et al.
https://t.me/med1917
561 Liu K, Wang ZQ, Wang SJ, Liu P, Qin YH, Ma Y, Li XC, Huo ZJ (2015) Hyaluronic acid-tagged
562 silica nanoparticles in colon cancer therapy: therapeutic efficacy evaluation. Int J Nanomedicine
563 10:6445. https://doi.org/10.2147/IJN.S89476
564 Liu W, Zhu Y, Wang F, Li X, Liu X, Pang J, Pan W (2018) Galactosylated chitosan-functionalized
565 mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. R Soc
566 Open Sci 5(12):181027. https://doi.org/10.1098 /rsos.181027
567 Lo PY, Lee GY, Zheng JH, Huang JH, Cho EC, Lee KC (2020) GFP plasmid and chemoreagent
568 conjugated with graphene quantum dots as a novel gene delivery platform for colon cancer
569 inhibition in vitro and in vivo. ACS Appl Bio Mater 3(9):5948–5956. https://doi.org/10.1021/
570 ACSABM.0C00631/ASSET/IMAGES/MEDIUM/MT0C00631_0010.GIF
571 Low LE, Tan LT, Goh BH, Tey BT, Ong BH, Tang SY (2019) Magnetic cellulose nanocrystal
572 stabilized Pickering emulsions for enhanced bioactive release and human colon cancer therapy.
573 Int J Biol Macromol 127:76–84. https://doi.org/10.1016/J.IJBIOMAC.2019.01.037
574 Lugoloobi I, Maniriho H, Jia L, Namulinda T, Shi X, Zhao Y (2021) Cellulose nanocrystals in
575 cancer diagnostics and treatment. J Control Release 336:207–232. https://doi.org/10.1016/
576 J.JCONREL.2021.06.004
577 Malik NS, Ahmad M, Minhas MU, Tulain R, Barkat K, Khalid I, Khalid Q (2020) Chitosan/
578 xanthan gum based hydrogels as potential carrier for an antiviral drug: fabrication, characteri-
579 zation, and safety evaluation. Front Chem 8:50. https://doi.org/10.3389/FCHEM.2020.00050/
580 BIBTEX
581 Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, Das S, Hanna G,
582 Park W, Chilkoti A, Koning GA (2012) Overcoming limitations in nanoparticle drug delivery:
583 triggered, intravascular release to improve drug penetration into tumors. Cancer Res 72(21):
584 5566–5575. https://doi.org/10.1158/0008-5472.CAN-12-1683
585 Marcelo GA, Montpeyo D, Novio F, Ruiz-Molina D, Lorenzo J, Oliveira E (2020) Luminescent
586 silicon-based nanocarrier for drug delivery in colorectal cancer cells. Dyes Pigments 181:
587 108393. https://doi.org/10.1016/J.DYEPIG.2020.108393
588 Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2020) Engineering
589 precision nanoparticles for drug delivery. Nat Rev Drug Discov 20(2):101–124. https://doi.org/
590 10.1038/s41573-020-0090-8
591 Mkam Tsengam IK, Omarova M, Kelley EG, McCormick A, Bothun GD, Raghavan SR, John VT
592 (2022) Transformation of lipid vesicles into micelles by adding nonionic surfactants: elucidating
593 the structural pathway and the intermediate structures. J Phys Chemi B 126(11):2208–2216.
594 https://doi.org/10.1021/acs.jpcb.1c09685
595 Moghimipour E, Rezaei M, Ramezani Z, Kouchak M, Amini M, Angali KA, Dorkoosh FA,
596 Handali S (2018) Folic acid-modified liposomal drug delivery strategy for tumor targeting of
597 5-fluorouracil. Eur J Pharm Sci 114:166–174. https://doi.org/10.1016/J.EJPS.2017.12.011
598 Näkki S, Wang JT, Wu J, Fan L, Rantanen J, Nissinen T, Kettunen MI, Backholm M, Ras RH,
599 Al-Jamal KT, Lehto VP (2019) Designed inorganic porous nanovector with controlled release
600 and MRI features for safe administration of doxorubicin. Int J Pharm 554:327–336. https://doi.
601 org/10.1016/J.IJPHARM.2018.10.074
602 Naseri N, Valizadeh H, Zakeri-Milani P (2015) Solid lipid nanoparticles and nanostructured lipid
603 carriers: structure, preparation and application. Adv Pharm Bull 5(3):305. https://doi.org/
604 10.15171/APB.2015.043
605 Neerooa BNHM, Ooi LT, Shameli K, Dahlan NA, Islam JMM, Pushpamalar J, Teow SY (2021)
606 Development of polymer-assisted nanoparticles and nanogels for cancer therapy: an update.
607 Gels 7(2):60. https://doi.org/10.3390/gels7020060
608 Ngwabebhoh FA, Erdagi SI, Yildiz U (2018) Pickering emulsions stabilized nanocellulosic-based
609 nanoparticles for coumarin and curcumin nanoencapsulations: in vitro release, anticancer and
610 antimicrobial activities. Carbohydr Polym 201:317– 328. https://doi.org/10.1016/J.CARBPOL.
611 2018.08.079
612 Osorio M, Martinez E, Naranjo T, Castro C (2020) Recent advances in polymer nanomaterials for
613 drug delivery of adjuvants in colorectal cancer treatment: a scientific-technological analysis and
614 review. Molecules 25(10):2270. https://doi.org/10.3390/MOLECULES25102270

Development of Biocompatible Nanocarriers for the Treatment of Colorectal Cancer 287
https://t.me/med1917
615Pang SW, Awi NJ, Armon S, Lim WWD, Low JSH, Peh KB, Peh SC, Teow SY (2019) Current
616update of laboratory molecular diagnostics advancement in management of colorectal cancer
617(CRC). Diagnostics 10(1):9. https://doi.org/10.3390/diagnostics10010009
618Park K (2013) Facing the truth about nanotechnology in drug delivery. ACS Nano 7(9):7442–7447.
619https://doi.org/10.1021/nn404501g
620Pishavar E, Ramezani M, Hashemi M (2019) Co-delivery of doxorubicin and TRAIL plasmid by
621modified PAMAM dendrimer in colon cancer cells, in vitro and in vivo evaluation. Drug Dev
622Ind Pharm 45(12):1931–1939. https://doi.org/10.1080/03639045.2019.1680995
623Prajapati SK, Jain A, Shrivastava C, Jain AK (2019) Hyaluronic acid conjugated multi-walled
624carbon nanotubes for colon cancer targeting. Int J Biol Macromol 123:691–703. https://doi.org/
62510.1016/J.IJBIOMAC.2018.11.116
626Priyadarshi K, Shirsath K, Waghela NB, Sharma A, Kumar A, Pathak C (2021) Surface modified
627PAMAM dendrimers with gallic acid inhibit, cell proliferation, cell migration and inflammatory
628response to augment apoptotic cell death in human colon carcinoma cells. J Biomol Struct Dyn
62939(18):6853–6869. https://doi.org/10.1080/07391102.2020.1802344
630Pushpamalar J, Meganathan P, Tan HL, Dahlan NA, Ooi LT, Neerooa BNHM, Essa RZ,
631Shameli K, Teow SY (2021) Development of a polysaccharide-based hydrogel drug delivery
632system (DDS): an update. Gels 7(4):153. https://doi.org/10.3390/gels7040153
633Rajabi M, Mousa A (2016) Lipid nanoparticles and their application in nanomedicine. Curr Pharm
634Biotechnol 17(8):662–672. https://doi.org/10.2174/1389201017666160415155457
635Ramezani P, Abnous K, Taghdisi SM, Zahiri M, Ramezani M, Alibolandi M (2020) Targeted
636MMP-2 responsive chimeric polymersomes for therapy against colorectal cancer. Colloids Surf
637B Biointerfaces 193:111135. https://doi.org/10.1016/J.COLSURFB.2020.111135
638Ramzy L, Metwally AA, Nasr M, Awad GA (2020) Novel thymoquinone lipidic core nanocapsules
639with anisamide-polymethacrylate shell for colon cancer cells overexpressing sigma receptors.
640Sci Rep 10(1):1–15. https://doi.org/10.1038/s41598-020-67748-2
641Rao S, Prestidge CA (2016) Polymer-lipid hybrid systems: merging the benefits of polymeric and
642lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv 13(5):691–707.
643https://doi.org/10.1517/17425247.2016.1151872
644Reimondez-Troitiño S, González-Aramundiz JV, Ruiz-Bañobre J, López-López R, Alonso MJ,
645Csaba N, de la Fuente M (2019) Versatile protamine nanocapsules to restore miR-145 levels and
646interfere tumor growth in colorectal cancer cells. Eur J Pharm Biopharm 142:449–459. https://
647doi.org/10.1016/J.EJPB.2019.07.016
648Rideau E, Dimova R, Schwille P, Wurm FR, Landfester K (2018) Liposomes and polymersomes: a
649comparative review towards cell mimicking. Chem Soc Rev 47(23):8572–8610. https://doi.org/
65010.1039/C8CS00162F
651Sabit H, Abdel-Hakeem M, Shoala T, Abdel-Ghany S, Abdel-Latif MM, Almulhim J, Mansy M
652(2022) Nanocarriers: a reliable tool for the delivery of anticancer drugs. Pharmaceutics 14(8):
6531566. https://doi.org/10.3390/pharmaceutics14081566
654Sandri SR, Bonferoni MC, Ferrari F, Mori M, Caramella C (2012) The role of chitosan as a
655mucoadhesive agent in mucosal drug delivery. J Drug Deliv Sci Technol 22(4):275–284. https://
656doi.org/10.1016/S1773-2247(12)50046-8
657Sauraj Kumar SU, Kumar V, Priyadarshi R, Gopinath P, Negi YS (2018) pH-responsive prodrug
658nanoparticles based on xylan-curcumin conjugate for the efficient delivery of curcumin in
659cancer therapy. Carbohydr Polym 188:252–259. https://doi.org/10.1016/j.carbpol.2018.02.006
660Scioli Montoto S, Muraca G, Ruiz ME (2020) Solid lipid nanoparticles for drug delivery: pharma-
661cological and biopharmaceutical aspects. Front Mol Biosci 7:319. https://doi.org/10.3389/
662FMOLB.2020.587997/BIBTEX
663Serini S, Cassano R, Corsetto PA, Rizzo AM, Calviello G, Trombino S (2018) Omega-3 PUFA
664loaded in resveratrol-based solid lipid nanoparticles: physicochemical properties and antineo-
665plastic activities in human colorectal cancer cells in vitro. Int J Mol Sci 19(2):586. https://
666doi.org/10.3390/IJMS19020586

288 B. N. H. M. Neeroa et al.
https://t.me/med1917
667 Shabbir R, Mingarelli M, Cabello G, Van Herk M, Choudhury A, Smith TA (2021) EGFR targeting
668 of [177Lu] gold nanoparticles to colorectal and breast tumour cells: affinity, duration of binding
669 and growth inhibition of Cetuximab-resistant cells. J King Saud Univ Sci 33(7):101573. https://
670 doi.org/10.1016/J.JKSUS.2021.101573
671 Shad PM, Karizi SZ, Javan RS, Mirzaie A, Noorbazargan H, Akbarzadeh I, Rezaie H (2020) Folate
672 conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor
673 and apoptosis efficacy on colorectal cancer cells (HT29 cell line). Toxicol In Vitro 65(1):
674 104756. https://doi.org/10.1016/J.TIV.2019.104756
675 Shen MY, Liu TI, Yu TW, Kv R, Chiang WH, Tsai YC, Chen HH, Lin SC, Chiu HC (2019)
676 Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/
677 thermotherapy delivery system for local treatment of colon cancer. Biomaterials 197:86–100.
678 https://doi.org/10.1016/J.BIOMATERIALS.2019.01.019
679 Sherje AP, Jadhav M, Dravyakar BR, Kadam D (2018) Dendrimers: A versatile nanocarrier for
680 drug delivery and targeting. Int J Pharm 548(1):707–720. https://doi.org/10.1016/j.ijpharm.
681 2018.07.030
682 Singhvi G, Hans N, Shiva N, Dubey SK (2019) Xanthan gum in drug delivery
683 applications. In: Natural polysaccharides in drug delivery and biomedical applications,
684 pp 121–144. https://doi.org/10.1016/B978-0-12-817055-7.00005-4
685 Sookkasem A, Chatpun S, Yuenyongsawad S, Wiwattanapatapee R (2015) Alginate beads for
686 colon specific delivery of self-emulsifying curcumin. J Drug Deliv Sci Technol 29:159–166.
687 https://doi.org/10.1016/J.JDDST.2015.07.005
688 Sun M, Wang T, Li L, Li X, Zhai Y, Zhang J, Li W (2021) The application of inorganic
689 nanoparticles in molecular targeted cancer therapy: EGFR targeting. Front Pharmacol 12:
690 1454. https://doi.org/10.3389/FPHAR.2021.702445/BIBTEX
691 Teow SY, Liew K, Ali SA, Khoo ASB, Peh SC (2016) Antibacterial action of curcumin against
692 Staphylococcus aureus: a brief review. J Trop Med 2016:2853045. https://doi.org/10.1155/
693 2016/2853045
694 Tomeh MA, Hadianamrei R, Zhao X (2019) A review of curcumin and its derivatives as anticancer
695 agents. Int J Mol Sci 20(5):1033. https://doi.org/10.3390/ijms20051033
696 Ways TM, Lau WM, Khutoryanskiy VV (2018) Chitosan and its derivatives for application in
697 mucoadhesive drug delivery systems. Polymers 10(3):267. https://doi.org/10.3390/
698 POLYM10030267
699 Wei Y, Gu X, Sun Y, Meng F, Storm G, Zhong Z (2020) Transferrin-binding peptide functionalized
700 polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. J Control
701 Release 319:407–415. https://doi.org/10.1016/J.JCONREL.2020.01.012
702 Wu P, Zhou Q, Zhu H, Zhuang Y, Bao J (2020) Enhanced antitumor efficacy in colon cancer using
703 EGF functionalized PLGA nanoparticles loaded with 5-fluorouracil and perfluorocarbon. BMC
704 Cancer 20(1):1–10. https://doi.org/10.1186/s12885-020-06803-7
705 Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol
706 14(10):101174. https://doi.org/10.1016/j.tranon.2021.101174
707 Xiao B, Viennois E, Chen Q, Wang L, Han MK, Zhang Y, Zhang Z, Kang Y, Wan Y, Merlin D
708 (2018) Silencing of intestinal glycoprotein CD98 by orally targeted nanoparticles enhances
709 chemosensitization of colon cancer. ACS Nano 12(6):5253–5265. https://doi.org/10.1021/
710 acsnano.7b08499
711 Xie YH, Chen YX, Fang JY (2020) Comprehensive review of targeted therapy for colorectal
712 cancer. Sig Transduct Target Ther 5:22. https://doi.org/10.1038/s41392-020-0116-z
713 Yadav HK, Almokdad AA, Sumia IM, Debe MS (2019) Polymer-based nanomaterials for drug-
714 delivery carriers. nanocarriers for drug delivery. In: Nanoscience and nanotechnology in drug
715 delivery, pp 531–556. https://doi.org/10.1016/B978-0-12-814033-8.00017-5

Development of Biocompatible Nanocarriers for the Treatment of Colorectal Cancer 289
https://t.me/med1917
716Ye H, Shen Z, Yu L, Wei M, Li Y (2018) Manipulating nanoparticle transport within blood flow
717through external forces: An exemplar of mechanics in nanomedicine. Proc Math Phys
718474(2211):20170845. https://doi.org/10.1098/rspa.2017.0845
719Yingchoncharoen P, Kalinowski DS, Richardson DR (2016) Lipid-based drug delivery systems in
720cancer therapy: what is available and what is yet to come. Pharmacol Rev 68(3):701. https://doi.
721org/10.1124/PR.115.012070
722Yusefi M, Shameli K (2021) Nanocellulose as a vehicle for drug delivery and efficiency of
723anticancer activity: a short-review. J Nanosci Nanotechnol 1(1):30–43. https://doi.org/
72410.37934/JRNN.1.1.3043
725Zheng B, Chen L, Pan CC, Wang JZ, Lu GR, Yang SX, Xue ZX, Wang FY, Xu CL (2018) Targeted
726delivery of miRNA-204-5p by PEGylated polymer nanoparticles for colon cancer therapy.
727Nanomedicine 13(7):769–785. https://doi.org/10.2217/nnm-2017-0345

Challenges of Onco-therapeutics
https://t.me/med1917
in Early-Onset Colorectal Cancer
Katie Doogan, Alexandra M. Zaborowski, and Des C. Winter
Abstract
The incidence of colorectal cancer among adults aged less than 50 is rising.
Patients with early-onset colorectal cancer are more likely to present with
advanced disease stage with requirements for multimodal treatment. Younger
patients appear to have higher rates of treatment-related toxicities, giving rise to
unique challenges for these patients. The impact of treatment-related morbidity
on quality of life can be overlooked. Survivorship issues are increasingly relevant
owing to the potential for long-term survival following treatment. Striking a
balance between treating early-onset colorectal cancer while preserving bowel,
bladder, sexual function, and fertility is challenging yet imperative.
Keywords
Chemotherapy · Early-onset colorectal cancer · Immunotherapy · Radiotherapy
1 Introduction
The incidence of early-onset colorectal cancer (age younger than 50) has increased
globally. Distinct clinical and pathological patterns have emerged. Patients with
early-onset colorectal cancer (EOCRC) frequently display unfavourable histopathological features and have advanced disease stage at presentation (Zaborowski et al.
2021a). Despite this, they have better or equivalent short-term and long-term
survival than patients with late-onset disease (Kneuertz et al. 2015; Saraste et al.
2020; Zaborowski et al. 2021a; AlZaabi et al. 2022). Young patients are also more
K. Doogan (✉) · A. M. Zaborowski · D. C. Winter
Centre for Colorectal Disease, St Vincent’s University Hospital, Dublin, Ireland
e-mail: doogank@tcd.ie
#
The Author(s), under exclusive license to Springer Nature Switzerland AG 2023
Interdisciplinary Cancer Research, https://doi.org/10.1007/16833_2023_148
Published online: 15 February 2023
291

292 K. Doogan et al.
https://t.me/med1917
likely to receive neoadjuvant chemoradiotherapy and adjuva nt chemotherapy than
their older counterparts and are also more likely to receive neoadjuvant and adjuvant
therapies outside of current treatment guidelines with minimal adjusted survival gain
(Kneuertz et al. 2015; Zaborowski et al. 2021a). The administration of intense
treatment may be related to better overall performance status and more advanced
disease stage at presentation (Bahadoer et al. 2022).
Receiving a cancer diagnosis at a younger age comes with unique challenges
compared to those in older age groups. Obstacles facing young patients with CRC
arise not only from the diagnosis and disease process but also from the prescribed
treatment. Patients with EOCRC are more likely to develop both disease- and
treatment-related long-term side effects (AlZaabi et al. 2022). These distressing
consequences are often under-recognised, with limited commentary in the literature.
Issues particularly pertinent to the young patients include fertility and family
planning concerns, responsibilities to young children, disruption to academic, working life and career ambitions, financial instability, and psychological impacts including a premature confrontation with mortality and a sense of lack of life completion or
attainment of life goals/milestones (Perl et al. 2016; AlZaabi et al. 2022; Eng et al.
2022). Younger age is a significant predictor for increased financial burden (Simard
et al. 2019). Young patients also report more psychological symptoms compared to
their older counterparts, including higher anxiety levels and negative body image
(Bailey et al. 2015).
With the focus on achieving disease control, the impact of treatment-related
morbidity on quality of life may be overlooked. Patient expectations that
complications may be only mild or temporary can make it more difficult to cope
with severe symptoms (Lim et al. 2021). Furthermore, survivors can attribute
symptoms with potential disease progression or recurrence triggering distress (Lim
et al. 2021). As survivorship improves, it is pertinent to consider quality of life when
deciding on treatment strategies. Clinicians should understand the challenges of
onco-therapeutics in managing early-onset colorectal cancers.
2 Total Neoadjuvant Therapy and the Potential
for Nonoperative Treatment
Trimodal treatment for rectal cancer (surgery, radiotherapy, and chemotherapy)
achieves good local control rates and long-term survival; however, multimodal
treatment is also associated with significant morbidity. Many long-term sequelae
are attributable to surgical resection. Patients achieving a pathological complete
response (pCR) following neoadjuvant therapy have lower local recurrence and
improved survival rates compared with those with a non-pCR (Park et al. 2012).
This therefore questions the added benefit of surgery in those who achieve a pCR.
Nonoperative management for patients with rectal cancer who achieve complete
clinical response following neoadjuvant chemotherapy is feasible, and surgical
resection may not lead to improved outcomes in select cases (Habr-Gama
et al. 2004). Total neoadjuvant therapy (TNT) where patients receive full-dose

Challenges of Onco-therapeutics in Early-Onset Colorectal Cancer 293
https://t.me/med1917
chemotherapy upfront in addition to radiotherapy has emerged as a potential option
to facilit ate organ preservation. This approach may be particularly attractive among
young patients (Eng et al. 2022). A substantial proportion of patients who undergo
surgery for EOCRC report a reduction in quality of life, and functional impairment is
unfortunately common. Patients with EOCRC are more likely to undergo more
complex operations for early-stage and metastatic disease (Siegel et al. 2020).
Dysfunction related to operative intervention can involve bowel-, urogenital-, and
fertility-related function (Bailey et al. 2015; Eng et al. 2022). Surgery can also
trigger lifestyle changes and inhibit participation in hobbies and socialising (Lim
et al. 2021). Therefore, the potential for nonoperative management is an attractive
option, enabling younger patients to evade potentially long-lasting bowel, urinary,
and sexual dysfunction associated with surgical resection. It is also of significant
consideration to EOCRC cancer patients who may want to avoid a stoma, temporary,
or permanent and the negative implications it can pose on quality of life, including
lower body image and poorer social activity, higher levels of depression and anxiety,
more pronounced sexual difficulties, sleep disturbance, and delayed return to work
(Baldwin et al. 2009; Lim et al. 2021; Cotrim and Pereira 2008; Traa et al. 2012;
Reese et al. 2014; den Bakker et al. 2020).
Advances in multimodality therapy have led to significantly improved local
control in rectal cancer. TNT should be considered in patients with high-risk locally
advanced rectal cancer owing to improved chemotherapy compliance in addition to
improved disease control (Zaborowski et al. 2019; Kong et al. 2021). Chemotherapy
is poorly tolerated after surgery for rectal cancer, and up to 50% of patients may not
complete planned cycles, and 25% may not receive any adjuvant chemotherapy
(Bosset et al. 2014). Additionally, TNT appears to have reduced toxicity compared
with adjuvant chemotherapy (REACCT Collaborative 2022a, b, c). Radiotherapy
has been shown to be more effective in the neoadjuvant setting, with greater
compliance rates than in the adjuvant setting (Beets 2021). TNT has ability to
overcome suboptimal complicate rates consistently observed with adjuvant therapy
(Zaborowski et al. 2019). Consistently poor adherence has been demonstrated.
Similar long-term oncological outcomes have been shown for patients with clinical
complete response and pathological complete response, adding to the attractiveness
of this option in suitable young candidates (Smith et al. 2012; Bahadoer et al. 2022).
One of the most promising potential advantages of TNT is the earlier delivery of
high-dose systemic chemotherapy aimed at eradicating occult micrometastases and
thereby reducing distant failure and improving long-term survival. Distant failure
rates remain high in rectal cancer, ranging between 20% and 30%, and remain the
most common form of treatment failure in patients with locally advanced rectal
cancer. A further potential advantage of TNT is that early optimisation of systemic
therapy may increase disease regression and improve pathological response rates.
Disease progression during high-dose chemotherapy is suggestive of unfavourable
treatment-resistant biology, in which case resection may be futile. In contrast, in
patients with marked tumour regression, organ preservation may be an appropriate
option, thereby facilitating a more selective practice of surgery (Zaborowski et al.
2019).

294 K. Doogan et al.
https://t.me/med1917
An important advantage of TNT is the potential to avoid radical surgical intervention. Both the safety and feasibility of offering a strict surveillance strategy has
been established in patients with a clinical complete response (cCR) after
neoadjuvant therapy (van der Valk et al. 2018; Garcia-Aguilar et al. 2020, 2022).
However, there remains hesitancy to offer organ preservation treatment to those aged
under 50 owing to a potentially higher oncological risk. Recent data comparing
young patients to their older counterparts following a watch-and-wait strategy after a
cCR demonstrated no additional oncological risk, with comparable disease-specific
survival, risk of local recurrence, and distant metastases (Bahadoer et al. 2022).
While undergoing surgical resection provides greater oncological certainty owing to
histological confirmation of tumour response, a watch-and-wait approach still should
be discussed with patients when a cCR is demonstrated after treatment based on
current evidence.
Limitations associated with a TNT strategy exist. Delay to definitive surgery is a
particular concern in patients who have poor response to CRT. In those with little or
no response to neoadjuvant CRT, a longer interval to surgery is associated with
worse overall and disease-free survival (Deidda et al. 2021). The aim should be to
identify poor responder early and proceed with surgery without delay. Adding to
this, neoadjuvant therapy can have a negative impact on performance status. Administration of full-dose systemic therapy may significantly affect fitness for surgery,
potentially resultin g in a prolonged interval to resection and/or higher postoperative
morbidity rates (Ludmir et al. 2017). In addition, delaying surgery may allow local
disease progression, resulting in more technically challenging dissection, increased
perioperative complications, and poorer overall survival (Zaborowski et al. 2019).
3 Challenges and Consequences of Pelvic Radiotherapy
Pelvic radiotherapy can cause bowel, urinary tract, and sexual organ dysfunction.
The term pelvic radiation disease (PRD) has been used to describe this, which can be
defined as ‘transient or longer-term problems, ranging from mild to very severe,
arising in non-cancerous tissues resulting from radiotherapy treatment to a tumour
located in the pelvis’ (Andreyev et al. 2011). Symptoms can range in severity, from
mild self-limiting conditions to debilitating symptoms with high morbidity. Acute
toxicity, occurring in the first 3 months following treatment, encompasses an
inflammatory response to radiation exposure, whereas small vessel disease, ischemia, and fibrosis underpin later toxicities (Dalsania et al. 2021). Despite newer, more
precise techniques in radiation delivery to the pelvis and rectum, almost all patients
still develop acute adverse effects (Tonneau et al. 2021).
Gastrointestinal toxicity is a common consequence of pelvic irradiation and can
be highly problematic for patients. Symptoms can include rectal bleeding, faecal
incontinence, and faecal urgency. Gastrointestinal symptoms have the most significant impact on quality of life after pelvic radiation (Andreyev et al. 2010). Almost all
patients receiving radical pelvic radiotherapy have a permanent change in bowel
function, with a reduction in quality of life in 50% of patients and severe effects in up

Challenges of Onco-therapeutics in Early-Onset Colorectal Cancer 295
https://t.me/med1917
to one-third of patients (Andreyev 2015). Radiation-induced gastrointestinal
symptoms affect as many patients each year as develop inflammatory bowel disease,
and as cancer therapy continues to improve with increased survivorship, gastrointestinal radiation toxicity will become a more prevalent health issue (Andreyev 2015;
Dalsania et al. 2021). Improvement techniques in radiation therapy in attempts to
reduce the amoun t of exposure to adjacent normal tissue have led to reduction in
acute toxicity; however, reduction of later toxicity is yet to be demonstrated (Klopp
et al. 2018). Concurrent chemotherapy and prior abdominal surgery contribute to
the development of longer-term complications (Dalsania et al. 2021). Toxic effects
can be progressive, with the need for operative intervention to manage these
complications increasing over time (Andreyev et al. 2011). Bowel dysfunction and
unpredictability, due to radiotherapy in addition to surgical intervention, cause
heightened anxiety and fear, exacerbating functional limitations and restrictions
survivors place on themselves, for example, alternating diet to accommodate
bowel function, staying at home, or near a toilet at all times (Lim et al. 2021).
Urological complications too occur following pelvic radiotherapy. Due to their
location, there is unavoidable radiation exposure of the bladder, urethra, and distal
ureters. This can lead to a broad range of debilitating outcomes for patients including
radiation cystitis; lower urinary tract dysfunction including frequency, urgency, and
nocturia; fistula formation; and stricture formation (Lobo et al. 2018). There does not
appear to be any difference in risk of developing urinary dysfunction between short
course and long course protocols (Guckenberger et al. 2013; Bregendahl et al. 2015).
Radiation-induced damage appears to cause higher rates of dysfunction than that
caused by operative intervention (Pollack et al. 2006; Beraldo et al. 2015). Management of these symptoms places a tremendous burden on the healthcare system,
disproportionally using more resources. Patients who require admission to hospital
under urology services to manage these complications have longer lengths of
hospital stays, have more operations, require more emergency surgeries, and have
higher readmission rates than other urology patients (Handmer et al. 2020).
Reproductive health and fertility are important considerations in young cancer
patients, and it is pertinent to address sexual health concerns early to limit wider
psychosocial effects (Reese et al. 2018). With the potential for prolonged survivorship in young patients and with sexual health playing a pivotal role in quality of life,
it is increasingly important to recognise these challenges. Rectal cancer patients tend
to report greater levels of sexual impairment; however, this may be due to combination effects of multimodal treatments including the effects of preoperative radiotherapy (Reese et al. 2018 ). Sexual dysfunction can act as an obstacle to reproduction.
Following radiothera py, almost 50% of men and 25% of women have difficulty
maintaining sexual relations (Brown et al. 2016). Future fertility is exceptionally
important to young cancer survivors (Teh et al. 2014). Multimodal treatment with a
combination of radiotherapy and chemotherapy will induce higher rates of
gonadotoxicity than either modality alone (Vakalopoulos et al. 2015). Pelvic radiotherapy can have detrimental effects on fertility in women, including premature
ovarian failure and permanent infertility (Spanos et al. 2008; Eng et al. 2022). Pelvic
radiation utilised in the treatment of rectal cancer exposed the ovaries to reasonable

296 K. Doogan et al.
https://t.me/med1917
doses of radiation, with a dose-dependent relationship between radiation and premature menopause (Maltaris et al. 2007; Wo and Viswanathan 2009). In addition, the
uterus is also the victim of radiation-included damage. If conception is achieved,
pregnancy maintenance is impacted by the development of fibrosis and a reduction
in uterine blood flow, uterine volume, and elasticity as a consequence of radiation
exposure (Maltaris et al. 2007; Teh et al. 2014). Miscarriage, placental
abnormalities, and premature labour are consequences (Spanos et al. 2008;Wo
and Viswanathan 2009). In addition, radiation therapy can also lead to sterility in
the male patient, due to effects on spermatogenesis (Vakalopoulos et al. 2015; Eng
et al. 2022). The impact of treatment on fertility must be explored with patients, and
options for fertility preservation discussed, particula rly in the era of increased access
to assisted reproductive technology. Data on how to best manage these toxicities is
lacking, with a limited evidence base for proposed treatments. This is true in the
management of rectal tumours and also applies to other pelvic malignancies where
radiotherapy forms part of the treatment plan (Dalsania et al. 2021). However, with
the emerging increased understanding of the underlying aetiology and molecular
mechanisms of radiation-induced toxicity, and ongoing efforts to focus the field of
radiation delivery, one can hope this can shed a light on effective treatment
mechanisms and reduce the burden of radiation-induced morbidity (Andreyev
2015).
4 Implications of Chemotherapeutics in Early-Onset
Colorectal Cancer
Younger patients are more likely to receive more intensive adjuvant chemotherapy
with minimal survival gains (Kneuertz et al. 2015; Eng et al. 2022). Currently there
is no difference in treatment recommendations between early- and later-onset
patients. Multiple acute toxicities can be problematic in young patients including
nausea, vomiting, acne, and alopecia (Eng et al. 2022). A consequence of this is the
impairment of typical day-to-day functioning. Loss of appetite and changes in taste
are also distressing side effects of chemotherapy agents (Ho et al. 2016).
Alternations in cognition are also of concern, impacting on occupational, familial,
and social life (Schagen et al. 2022). Psychological unmet needs are of greater
prevalence than physical unmet needs in advanced colorectal cancer patients receiving chemotherapy (Sakamoto et al. 2017). Lower self-esteem, reduced social functioning, and negative body image all negatively affect quality of life in patients
receiving chemotherapy (Eng et al. 2022).
Long-term sequelae and chronic side effects of chemotherapy can have a substantial and ongoing impact on quality of life (Eng et al. 2022). Peripheral neuropathy is a leading cause of long-term morbidity, with chemotherapy-induced peripheral
neuropathy having a negative association with quality of life in cancer survivors,
with the potential for symptoms to persist for years following cessation of treatment
Соседние файлы в папке Библиотека им академика М.И. Перельмана
